Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes

Background Metabolic-associated fatty liver disease (MAFLD) is increasingly common among people living with the human immunodeficiency virus (PLHIV) and can progress to cirrhosis and cirrhotic-related complications. Pioglitazone is known to improve insulin sensitivity that results in decreasing seru...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamolvisit, Sarunporn, Chirnaksorn, Supphamat, Nimitphong, Hataikarn, Sungkanuparph, Somnuek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613454/
https://www.ncbi.nlm.nih.gov/pubmed/34858740
http://dx.doi.org/10.7759/cureus.19046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613454/
https://www.ncbi.nlm.nih.gov/pubmed/34858740
http://dx.doi.org/10.7759/cureus.19046

Ejemplares similares